Skip to main content
Clinical Trials/ISRCTN62683103
ISRCTN62683103
Active, not recruiting
Phase 3

A prospective, randomized controlled trial to evaluate correction of ridge contour deficiency using OSSIX® Volumax vs Fibro-Gide.

Datum Dental0 sites65 target enrollmentOctober 18, 2022

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Dental ridge contour deficiency
Sponsor
Datum Dental
Enrollment
65
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 18, 2022
End Date
March 1, 2025
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Datum Dental

Eligibility Criteria

Inclusion Criteria

  • 1\. Males and females \=18 years
  • 2\. General good health (ASA 1 and ASA 2\)
  • 3\. Presence of a tissue contour deficiency leading to an unesthetic implant rehabilitation, not associated with bone dehiscence and/or fenestration defects.
  • 4\. Patients require 1\-3 implants placed between two periodontally stable natural teeth.
  • 5\. Good oral hygiene (full mouth plaque index \<25%)
  • 6\. Adequate control of inflammation (full mouth bleeding on probing \<25%)
  • 7\. Patients that are willing to sign an informed consent and participate in the clinical study
  • 8\. Patient that are able to understand and to comply with the study related procedures such as exercising good oral hygiene and attending all follow\-up examinations

Exclusion Criteria

  • 1\. Implant sites with associated alveolar bone dehiscence and/or fenestration defects that necessitate bone grafting in combination with correction of ridge contour deficiency.
  • 2\. General contraindications for dental and/or surgical treatments
  • 3\. Inflammatory and autoimmune disease of the oral cavity
  • 4\. Allergy to collagen
  • 5\. Uncontrolled diabetes (A1C \> 6\.5 %)
  • 6\. Disease of oral mucosa
  • 7\. Disease affecting connective tissue metabolism (e.g. collagenases)
  • 8\. Uncontrolled Periodontal disease
  • 9\. History of myeloma, respiratory tract cancer, breast cancer, prostate cancer, or kidney cancer requiring chemotherapy or radiotherapy.
  • 10\. Concurrent or previous radiotherapy of head area

Outcomes

Primary Outcomes

Not specified

Similar Trials